FORMULATION ARTICLES
-
![double stranded circular rna-GettyImages-2220593312]( "Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics")
Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA TherapeuticsCircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.
-
![drug delivery, nanotechnology technology-GettyImages-1337413453]( "Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery")
Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic DiscoveryAs RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.
-
![Small interfering RNA, sirna, mrna, crispr-GettyImages-1409578453]( "Building A Self-Driving Lab For LNP Development")
Building A Self-Driving Lab For LNP DevelopmentWith commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.
-
![technology and science-GettyImages-1440932538]( "Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA Fate")
Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA FateHow do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.
-
![DNA target nanodrugs-GettyImages-1405926704]( "Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient Disease")
Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient DiseaseCan RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.
-
![Small interfering RNA, sirna, mrna, crispr-GettyImages-1409578453]( "Beyond The m⁷G Cap: How Non-Canonical RNA Capping Could Expand RNA Therapeutics")
Beyond The m⁷G Cap: How Non-Canonical RNA Capping Could Expand RNA TherapeuticsNewly discovered non-canonical RNA caps are reshaping RNA biology and could inspire the next generation of more precise, programmable RNA therapeutics.
FORMULATION VIDEOS
Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.
Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.
Unlock next-generation nanoparticle and LNP manufacturing. Achieve high throughput, minimal waste, and superior quality with a compact, automated, and contamination-controlled system.
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![Precision NanoSystems Feature]( "Understanding The Microfluidic Platforms For Scaling Nanoparticle Production")
Learn about the benefits of microfluidics for nanoparticle production over traditional methods as well as scaling nanoparticle production for clinical or industrial use.
-
![Digital DNA technology-GettyImages-1414458419]( "Achieving Speed And Scale With Optimized Synthesis Solutions")
Realize optimal coupling efficiency and increase your productivity for oligonucleotide drugs by selecting the right synthesizer and prioritizing automation to define and tweak synthesis methods.
-
![GettyImages-1264101698-lab-research-scientist]( "Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications")
Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.
-
![GettyImages-2270210340-lipid-nanoparticle-delivery-system]( "Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles")
Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Lowering The Lipid Barrier To RNA-LNP Therapeutics")
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.
-
![Cryoport]( "Why Risk Analysis And Lane Qualification Matter")
Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.
-
![GettyImages-1194781834-cell]( "mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations")
Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.
